The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Phagocytosis and inflammation within the lungs is crucial for host defense during bacterial pneumonia. Triggering receptor expressed on myeloid cells (TREM)-2 was proposed to negatively regulate TLR-mediated responses and enhance phagocytosis by macrophages, but the role of TREM-2 in respiratory tract infections is unknown. Here, we established the presence of TREM-2 on alveolar macrophages (AM) and explored the function of TREM-2 in the innate immune response to pneumococcal infection in vivo. Unexpectedly, we found Trem-2(-/-) AM to display augmented bacterial phagocytosis in vitro and in vivo compared to WT AM. Mechanistically, we detected that in the absence of TREM-2, pulmonary macrophages selectively produced elevated complement component 1q (C1q) levels. We found that these increased C1q levels depended on peroxisome proliferator-activated receptor-δ (PPAR-δ) activity and were responsible for the enhanced phagocytosis of bacteria. Upon infection with S. pneumoniae, Trem-2(-/-) mice exhibited an augmented bacterial clearance from lungs, decreased bacteremia and improved survival compared to their WT counterparts. This work is the first to disclose a role for TREM-2 in clinically relevant respiratory tract infections and demonstrates a previously unknown link between TREM-2 and opsonin production within the lungs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Furthermore, recent evidence shows individuals who possess heterozygous rare variants of TREM-2 are at increased risk of Alzheimer’s disease [14,15].”
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434
Apoptotic cell clearance: basic biology and therapeutic potential
Poon, I. K. H., Lucas, C. D., Rossi, A. G., & Ravichandran, K. S. (2014) · Nature Reviews Immunology · doi:10.1038/nri3607 · Cited by 1,223 · cited 2×
“which promotes the resolution of inflammation [53,54,55,56].”
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Cutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688
Self-citationSchröder, N. W. J., Morath, S., Alexander, C., Hamann, L., Hartung, T., Zähringer, U., Göbel, U. B., Weber, J. R., & Schumann, R. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212829200 · Cited by 641
Sun, K., & Metzger, D. W. (2008) · Nature Medicine · doi:10.1038/nm1765 · Cited by 587 · cited 2×
“pneumoniae [29,39].”
A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475 · cited 2×
“Furthermore, although TREM-2 has been shown to be a phagocytic receptor for apoptotic neurons [11], uptake of microspheres is unchanged following knockdown of TREM-2, indicating TREM-2 is not essential for all types of phagocytosis [63].”
Bouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460
Self-citationHamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440 · cited 2×
“Much to our surprise, since TREM-2 was earlier considered a negative regulator of inflammation [10,20], we did not identify any differences in levels of several inflammatory mediators tested, such as TNF-a, MCP-1, IL-1b and IL-6 (Fig.”
Cited by
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Lung Single-Cell Signaling Interaction Map Reveals Basophil Role in Macrophage Imprinting
Cohen, M., Giladi, A., Gorki, A.-D., Solodkin, D. G., Zada, M., Hladik, A., Miklosi, A., Salame, T.-M., Halpern, K. B., David, E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.009 · Cited by 421
Self-citationTLR4 Cross-Talk With NLRP3 Inflammasome and Complement Signaling Pathways in Alzheimer's Disease
Yang, J., Wise, L., & Fukuchi, K.-I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00724 · Cited by 387
TREM2-Ligand Interactions in Health and Disease
Kober, D. L., & Brett, T. J. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.004 · Cited by 284
First-Breath-Induced Type 2 Pathways Shape the Lung Immune Environment
Saluzzo, S., Gorki, A.-D., Rana, B. M. J., Martins, R., Scanlon, S., Starkl, P., Lakovits, K., Hladik, A., Korosec, A., Sharif, O., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.071 · Cited by 255
Self-citationNuclear Receptors License Phagocytosis by Trem2+Myeloid Cells in Mouse Models of Alzheimer's Disease
Savage, J. C., Jay, T., Goduni, E., Quigley, C., Mariani, M. M., Malm, T., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4586-14.2015 · Cited by 154
“TREM2 has recently been reported to have analogous proinflammatory actions in murine models of stroke (Sieber et al., 2013), colitis (Correale et al., 2013), and lung inflammation (Sharif et al., 2014).”
Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions
Martins, R., Maier, J., Gorki, A.-D., Huber, K. V. M., Sharif, O., Starkl, P., Saluzzo, S., Quattrone, F., Gawish, R., Lakovits, K., et al. (2016) · Nature Immunology · doi:10.1038/ni.3590 · Cited by 142
Self-citationNon-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
Perugorria, M. J., Esparza-Baquer, A., Oakley, F., Labiano, I., Korosec, A., Jais, A., Mann, J., Tiniakos, D., Santos-Laso, A., Arbelaiz, A., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-314107 · Cited by 144
Self-citationHuang, P., Zhang, Z., Zhang, P., Feng, J., Xie, J., Zheng, Y., Liang, X., Zhu, B., Chen, Z., Feng, S., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-023-03713-0 · Cited by 111
Iizasa, E., Chuma, Y., Uematsu, T., Kubota, M., Kawaguchi, H., Umemura, M., Toyonaga, K., Kiyohara, H., Yano, I., Colonna, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22620-3 · Cited by 92
Self-citationQu, W., Wang, Y., Wu, Y., Liu, Y., Chen, K., Liu, X., Zou, Z., Huang, X., & Wu, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01121 · Cited by 40
Metadata
- Authors
- Sharif, O., Gawish, R., Warszawska, J. M., Martins, R., Lakovits, K., Hladik, A., Doninger, B., Brunner, J., Korosec, A., Schwarzenbacher, R. E., Berg, T., Kralovics, R., Colinge, J., Mesteri, I., Gilfillan, S., Salmaggi, A., Verschoor, A., Colonna, M., & Knapp, S.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-12
- Volume
- 10
- Issue
- 6
- Pages
- e1004167
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1978554459
- Cited by
- 60
- References
- 16
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.